Orforglipron vs CagriSema
Compare the research profiles of Orforglipron and CagriSema. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesOrforglipron
Orforglipron (LY3502970)
weight-loss
Phase 3 Clinical Trials
clinical-trials
CagriSema
CagriSema (Semaglutide + Cagrilintide)
weight-loss
Phase 3 Clinical Trials
clinical-trials
Detailed Comparison
| Aspect | Orforglipron | CagriSema |
|---|---|---|
| Overview | The most anticipated upcoming weight loss drug - the first oral non-peptide GLP-1 receptor agonist. Unlike current oral options, it does not require fasting before consumption, potentially removing a ... | A next-generation combination therapy by Novo Nordisk combining semaglutide with cagrilintide (an amylin analogue). Aims for even stronger weight loss effects than Wegovy alone.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Small molecule that activates GLP-1 receptors orally without the peptide structure. Provides similar effects to injectable GLP-1s but in pill form.... | Dual mechanism: semaglutide activates GLP-1 receptors while cagrilintide mimics amylin, a hormone that slows gastric emptying and promotes satiety. Th... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.